Home

Pfizer (PFE)

23.37
+0.37 (1.60%)
NYSE · Last Trade: May 20th, 12:33 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close23.00
Open23.17
Bid23.36
Ask23.37
Day's Range23.16 - 23.70
52 Week Range20.92 - 31.54
Volume33,468,119
Market Cap131.02B
PE Ratio (TTM)16.93
EPS (TTM)1.4
Dividend & Yield1.720 (7.36%)
1 Month Average Volume49,061,551

Chart

About Pfizer (PFE)

Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More

News & Press Releases

The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped.investors.com
The new framework limits future Covid shots to people age 65 and older and those six months and older with a risk factor for serious illness.
Via Investor's Business Daily · May 20, 2025
WeRide Teams Up With Tencent Cloud To Accelerate Global Robotaxi Ambitionsstocktwits.com
The company said Tencent Cloud will allow it to offer localized and compliant cloud services in countries outside of China, accelerating the commercial rollout of its robotaxi services overseas.
Via Stocktwits · May 20, 2025
Pfizer Strikes Deal With China’s 3SBio For Experimental Cancer Drug Licensestocktwits.com
3SBio’s experimental cancer drug is currently undergoing clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors.
Via Stocktwits · May 20, 2025
Sell-Off Grips Dalal Street: Nifty Ends Below 24,700; Metals Shine On China Rate Cutstocktwits.com
Indian markets ended sharply lower, dragged by broad-based profit booking, FPI outflows, and fading optimism over the U.S.-India trade deal.
Via Stocktwits · May 20, 2025
These 3 Dividend Stocks Yield More Than 6% and Their Payouts Look Safefool.com
Via The Motley Fool · May 20, 2025
Pfizer Secures Global Rights To China's 3SBio's Cancer Drug In $6 Billion Dealbenzinga.com
Pfizer Inc. announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.'s bispecific antibody SSGJ-707.
Via Benzinga · May 19, 2025
Retail Bulls Cheer FDA Clearance For BrainStorm’s ALS Therapy, But Shares Dip After Hoursstocktwits.com
BrainStorm Cell Therapeutics plans to enroll 200 ALS patients in its FDA-cleared Phase 3b trial of NurOwn, with a 24-week double-blind phase followed by an open-label extension.
Via Stocktwits · May 19, 2025
Pfizer Enters into Exclusive Licensing Agreement with 3SBio
Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. SSGJ-707 has shown initial efficacy and safety data in a promising class of cancer medicines. 3SBio plans to initiate the first Phase 3 study in China in 2025.
By Pfizer Inc. · Via Business Wire · May 19, 2025
Ireland: America’s Gateway to Europe – The $2 Trillion Investment Story
Ireland has emerged as the undisputed champion in attracting U.S. foreign direct investment, hosting an extraordinary €897 billion (over $1 trillion) in American capital. This massive investment flow has transformed the small island nation into America's premier European platform, with U.S. affiliate assets reaching approximately $2 trillion in 2021.
Via AB Newswire · May 19, 2025
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Paymentbenzinga.com
Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall.
Via Benzinga · May 19, 2025
Novavax Wins Limited FDA Nod For COVID Shot—Cleared Only For Seniors, High-Risk Groups Amid Safety Scrutinybenzinga.com
The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions that increase risk of severe illness.
Via Benzinga · May 19, 2025
1 Profitable Stock on Our Watchlist and 2 to Turn Down
A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Via StockStory · May 19, 2025
India Market Watch: Muted Start For Nifty, Sensex — Defense Stocks, Delhivery Shinestocktwits.com
Via Stocktwits · May 19, 2025
Novavax Wins FDA Approval For COVID-19 Vaccine: Retail Calls For Buyback And Bigger Movesstocktwits.com
The pharma company secured FDA clearance to manufacture and distribute its COVID-19 vaccine Nuvaxovid for adults and at-risk groups, with no advisory committee hurdles.
Via Stocktwits · May 18, 2025
Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.fool.com
Here are three dividend-paying stocks that warrant closer examination.
Via The Motley Fool · May 18, 2025
Analyst Ethan Billings shares insights on tech stocks
Ethan Billings, a securities analyst at TD Securities’ Washington branch, publicly recommended in the WhatsApp trading strategy group to gradually start buying tech stocks beginning April 20. The strategy has led to significant profits. Below is a detailed breakdown of the recommended tech stocks.
Via Binary News Network · May 16, 2025
Here's How Many Shares of Pfizer You Should Own to Make $10,000 in Annual Dividend Incomefool.com
Via The Motley Fool · May 16, 2025
3 Profitable Stocks to Research Further
Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financial discipline.
Via StockStory · May 16, 2025
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025benzinga.com
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.
Via Benzinga · May 15, 2025
What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocksfool.com
Via The Motley Fool · May 15, 2025
3 Magnificent S&P 500 Dividend Stocks Down 62%, 63%, and 64% to Buy and Hold Foreverfool.com
Temporary turbulence has resulted in opportunity for patient, bargain-hunting investors.
Via The Motley Fool · May 14, 2025
Curious about the most active S&P500 stocks in today's session?chartmill.com
Looking for the most active stocks in the S&P500 index on Wednesday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market.
Via Chartmill · May 14, 2025
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030benzinga.com
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.
Via Benzinga · May 14, 2025
3 Value Stocks Facing Headwinds
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Via StockStory · May 14, 2025
Jim Cramer Is 'OK' With Harrow, Recommends Buying This Energy Stockbenzinga.com
Jim Cramer takes a look at Harrow, Pfizer, Kinsale Capital, Manulife Financial, Iron Mountain and more on "Mad Money."
Via Benzinga · May 13, 2025